Clinical trial NCT03563846: Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Adult Male and Female Subjects
Official title: Prospective, Open-Label, Randomized, Two-Period, Two-Sequence, Crossover Study Comparing RP-G28 Administered in the Fasted State and the Effect of a Standard Meal on the Pharmacokinetic Profile of RP-G28 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lactose Intolerance
Lead sponsor: Ritter Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2018-06-20
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Randomized, open-label, 2-period, 2-sequence, crossover study to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28.

Detailed description: This randomized, open-label, 2-period, 2-sequence, crossover study is designed to evaluate the effect of a standard meal on the pharmacokinetic (PK) profile of orally administered RP-G28, which is being developed for the treatment of lactose intolerance. The study consists of a screening visit (during the interval from Day -21 to Day -3), baseline/check-in to the clinical research unit (Day -2 to Day -1), 2 treatment periods (Day 1 and Day 3), a 48-hour washout between doses, check-out from the clinical research unit (Day 4), and 1 follow-up phone call conducted 7 to 10 days after the final dose of the study drug (i.e., during the interval from Day 10 to Day 13). The duration of subject study participation is approximately 5 weeks. Plasma samples for PK analysis will be taken at specified timepoints from 24 hours prior to each dose through 24 hours after each dose.

Eligibility criteria: Inclusion Criteria:

1. Healthy male and female subjects between 18 and 60 years of age
2. Subjects with body weights greater than or equal to 50 kg and a body mass index (BMI) between 18 kg/m2 and 32 kg/m2
3. Female subjects of childbearing potential and males and their female partner(s) of childbearing potential must agree to use 2 forms of contraception, 1 of which must be a barrier method, during the study and for 30 days after the end of the study

Exclusion Criteria:

1. Pregnant or lactating females or male partners of females who are pregnant or lactating.
2. Subjects with any history of clinically significant bronchopulmonary, cardiovascular, cerebrovascular, hematologic, renal, hepatic, neurological, psychiatric, metabolic, or endocrine (eg, diabetes or thyroid disease) disease/disorder.
3. Use of prescription or over-the-counter (OTC) drugs, including vitamins and herbal or dietary supplements within 2 weeks (4 weeks for enzyme inducers including St. John's Wort) or 5 half-lives (whichever is longer), prior to the baseline/check-in visit, unless in the opinion of the investigator, prior use of the medication will not interfere with the study procedures or compromise subject safety.
4. Subjects with sustained supine or semi-supine systolic blood pressure of \< 90 or \> 140 mm Hg and supine or semi-supine diastolic blood pressure of \< 50 or \> 90 mm Hg at the screening or baseline/check-in visits.
5. Subjects with a resting heart rate of \< 45 or \> 100 beats per minute at the screening or baseline/check in visits.
6. Subjects with any clinically relevant deviation from normal during the physical examination, including vital signs at the screening or baseline/check-in visits.
7. Subjects with a known history of hypercalcemia, hyperparathyroidism, or hypervitaminosis D.
8. Use of calcium or vitamin D supplements (prescription or OTC) within 2 weeks prior to the baseline/check-in visit.
9. Subjects with a history of allergic reactions or hypersensitivities to galacto-oligosaccharides or any significant drug-related or food-related allergy (such as anaphylaxis or hepatotoxicity).
10. Regular use of probiotics, antacids, histamine type 2 (H2)-receptor blockers, proton pump inhibitors, or any medications that may alter the normal gastric environment and/or motility, or use of such medications within 2 weeks prior to the baseline/check-in visit.

Primary outcomes:
measure: Area under the plasma concentration-time curve from time 0 extrapolated to infinity
timeFrame: Days 2 and 1 pretreatment; Day 1 post-treatment, Day 1-3 washout, Day 3 and 4 post-treatment
Secondary outcomes:
measure: Adverse events
timeFrame: 2, 3, 2 and 1 days pretreatment; 1 - 13 days post-treatment
measure: Serum chemistry
timeFrame: 21 and 3 days pretreatment; day 4 post-treatment
measure: Hematology
timeFrame: 21 and 3 days pretreatment; day 4 post-treatment
measure: Urinalysis
timeFrame: 2, 3, 2 and 1 days pretreatment; day 1 and 3 post-treatment
Other outcomes:
Locations:
city: Miami
country: United States
facility: Syneos Health
state: Florida
Study officials:
affiliation: Ritter Pharmaceuticals
name: Paul G Pearson, PhD
role: STUDY_DIRECTOR
References: